Literature DB >> 19111581

Lysosomal disorders: from storage to cellular damage.

Andrea Ballabio1, Volkmar Gieselmann.   

Abstract

Lysosomal storage diseases represent a group of about 50 genetic disorders caused by deficiencies of lysosomal and non-lysosomal proteins. Patients accumulate compounds which are normally degraded in the lysosome. In many diseases this accumulation affects various organs leading to severe symptoms and premature death. The revelation of the mechanism by which stored compounds affect cellular function is the basis for understanding pathophysiology underlying lysosomal storage diseases. In the past years it has become clear that storage compounds interfere with various processes on the cellular level. The spectrum covers e.g. receptor activation by non-physiologic ligands, modulation of receptor response and intracellular effectors of signal transduction cascades, impairment of autophagy, and others. Importantly, many of these processes are associated with accumulation of storage material in non-lysosomal compartments. Here we summarize current knowledge on the effects that storage material can elicit on the cellular level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19111581     DOI: 10.1016/j.bbamcr.2008.12.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  200 in total

Review 1.  Pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Cinzia Maria Bellettato; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-04-29       Impact factor: 4.982

Review 2.  Common and uncommon pathogenic cascades in lysosomal storage diseases.

Authors:  Einat B Vitner; Frances M Platt; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

3.  TM7SF1 (GPR137B): a novel lysosome integral membrane protein.

Authors:  Jialin Gao; Libin Xia; Meiqing Lu; Binhua Zhang; Yueping Chen; Rang Xu; Lizhuo Wang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

4.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

Review 5.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

6.  Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.

Authors:  Eugenia Trushina; Christie A Canaria; Do-Yup Lee; Cynthia T McMurray
Journal:  Hum Mol Genet       Date:  2013-09-10       Impact factor: 6.150

Review 7.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

8.  Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased 1H NMR-Linked Metabolomics Strategy.

Authors:  Benita C Percival; Yvonne L Latour; Cynthia J Tifft; Martin Grootveld
Journal:  Cells       Date:  2021-03-05       Impact factor: 6.600

Review 9.  The role of ceramides in metabolic disorders: when size and localization matters.

Authors:  Sarah M Turpin-Nolan; Jens C Brüning
Journal:  Nat Rev Endocrinol       Date:  2020-02-14       Impact factor: 43.330

Review 10.  Lysosomal storage diseases.

Authors:  Frances M Platt; Alessandra d'Azzo; Beverly L Davidson; Elizabeth F Neufeld; Cynthia J Tifft
Journal:  Nat Rev Dis Primers       Date:  2018-10-01       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.